The biocompatibility testing services market is witnessing substantial growth as regulatory requirements for medical products become increasingly stringent across healthcare and life sciences industries. The global biocompatibility testing services market size was estimated at USD 5.1 billion in 2025 and is projected to reach USD 10.6 billion by 2033, growing at a CAGR of 9.7% from 2026 to 2033. A major factor fueling market expansion is the rising need for regulatory compliance and adherence to ISO 10993 standards. Manufacturers of medical devices and healthcare products are required to conduct comprehensive biological assessments before receiving regulatory approval or implementing modifications to existing devices. As product safety remains a top priority for regulators and healthcare providers, the demand for specialized biocompatibility testing services continues to increase across the development lifecycle.

Another significant driver contributing to market growth is the increasing demand for biologics and combination products. The growing use of advanced drug delivery systems, biologic therapies, and combination medical products has intensified the need for extractable and leachable testing. These tests play a critical role in evaluating potential chemical interactions between pharmaceutical products and packaging materials, particularly in drug container-closure system applications. As pharmaceutical and biotechnology companies focus on product quality, patient safety, and regulatory compliance, the demand for advanced testing solutions is expected to rise steadily, creating new growth opportunities for service providers operating in the biocompatibility testing ecosystem.

Download a free sample copy of the Biocompatibility Testing Services market report to understand detailed coverage and inclusions in the final report

Key Market Trends & Insights

·         Regional analysis indicates that North America dominated the market, accounting for the largest global share of 47.0% in 2025. The region's leadership can be attributed to its advanced healthcare infrastructure, strong regulatory framework, and significant investments in medical device and pharmaceutical research. Furthermore, the U.S. biocompatibility testing services industry is expected to grow significantly from 2026 to 2033, supported by increasing innovation in medical technologies and the growing adoption of biologics and combination products.

·         Based on test type, the material/chemical characterization segment held the largest market share in 2025. Material and chemical characterization testing is essential for identifying potential risks associated with materials used in medical devices and pharmaceutical products. These assessments provide critical information regarding product safety, helping manufacturers meet regulatory requirements and accelerate approval processes.

·         Based on development stage, the clinical segment held the largest market share in 2025. Clinical-stage testing plays a vital role in validating the safety and effectiveness of products before commercialization. The growing number of clinical studies and increasing regulatory scrutiny are expected to support continued demand for biocompatibility testing services throughout the forecast period.

·         Based on industry application, the medical device segment held the largest market share in 2025. Medical device manufacturers rely heavily on biocompatibility assessments to ensure product safety and compliance with regulatory standards. The ongoing development of innovative implantable devices, diagnostic equipment, and therapeutic technologies is expected to sustain strong demand for testing services within this segment.

Looking for more specific insights? Customize this report to suite your business needs

Key Companies & Market Share Insights

The competitive landscape remains highly dynamic, with key market participants focusing on strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and geographic expansions to strengthen their market positions. These strategies enable companies to enhance their service portfolios, expand technical capabilities, and meet evolving customer requirements. For instance, in January 2026, NAMSA acquired select assets of Labcorp’s early development medical device testing business, expanding its capabilities and giving it an edge in biocompatibility, microbiology, and preclinical testing services. Such developments are expected to intensify competition while supporting innovation and service quality improvements across the market.

With increasing regulatory requirements, growing adoption of biologics, expanding medical device innovation, and rising demand for comprehensive safety assessments, the biocompatibility testing services market is poised for sustained growth through 2033. Industry participants that invest in advanced testing technologies, regulatory expertise, and strategic collaborations are expected to capitalize on emerging opportunities and strengthen their market presence in the years ahead.

Key Biocompatibility Testing Services Companies:

·        NAMSA

·        Eurofins Scientific SE

·        SGS SA

·        Intertek Group

·        Charles River

·        Nelson Laboratories, LLC

·        Pacific BioLabs

·        Labcorp (Toxikon Corporation)

·        Medistri SA

·        Wickham Laboratories

·        Pace Analytical Services

Grand View Research offers

·         Focused market intelligence reports on specific geographies or high-growth segments.

·         Extended forecast timelines for long-term planning.

·         Competitor Benchmarking and Supply Chain Analysis

·         Inclusion of regulatory and policy assessments.

·         Inclusion of custom data models, KPIs, or applications unique to your business

·         Specific high-impact Data Decks and Tables to support effective decision making

·         And much more…

Looking for a report customized to your requirements? Explore our Custom Research Offering